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OBJECTIVES: To evaluate serological markers of gluten sensitivity in conjunction with cholecystokinin 
measurement in Border terriers with gall bladder mucocoeles.
MATERIALS AND METHODS: Medical records from two referral hospitals were obtained between 2011 and 
2019 to identify Border terriers with gall bladder mucocoeles, non-Border terriers with gall bladder 
mucocoeles and control Border terriers with non-biliary diseases. Enzyme-linked immunosorbent 
assays were performed on stored fasted serum samples for anti-gliadin IgG, anti-canine transglutami-
nase-2-IgA autoantibodies and cholecystokinin. Statistical analysis was performed using the Kruskall-
Wallis test to identify differences between the groups.
RESULTS: Fifteen Border terriers with gall bladder mucocoeles, 17 non-Border terriers with gall bladder 
mucocoeles and 14 control Border terriers with non-biliary diseases were recruited. Median transglu-
taminase-2-IgA autoantibodies in Border terriers with gall bladder mucocoeles was 0.73 (range: 0.18 
to 1.67), which was significantly greater than in control Border terriers at 0.41 (0.07 to 1.14). Median 
cholecystokinin concentration in Border terriers with gall bladder mucocoeles was 13 pg/mL (6 to 45 
pg/mL), which was significantly lower than in control Border terriers at 103 pg/mL (9 to 397 pg/mL). 
There was no difference in the anti-gliadin IgG between these groups. There was no difference 
observed in the non-Border terriers with gall bladder mucocoeles with either of the other groups.
CLINICAL SIGNIFICANCE: Reduced cholecystokinin and increased transglutaminase-2-IgA autoantibodies 
was detected in Border terriers with gall bladder mucocoeles; which is in part homologous to gall 
bladder disease identified in human coeliac disease. The results suggest an immunological disease 
with impaired cholecystokinin release may be affecting gall bladder motility and possibly contributing 
to mucocoele formation in Border terriers.
Funding for this study was obtained from the PetPlan Charitable Trust, as a pump primer 
grant.
Sections of the data were submitted for presentation at the BSAVA congress in Birmingham, 
April 2020.
The primary author’s current position is sponsored by Boehringer Ingelheim Vetmedica. 
However, this company has no affiliation or financial involvement with this manuscript.
There is no off-label antimicrobial use.
INTRODUCTION
Gall bladder mucocoele (GBM) is a biliary disorder recognised in 
dogs and is characterised by an abnormal accumulation of semi-
solid bile or mucus that results in varying degrees of distension of 
the gall bladder and biliary duct obstruction (Aguirre et al. 2007).
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Reports of GBM have recently increased, suggesting an 
emerging phenomenon, and with no comparable condition in 
humans, this has prompted investigations into the pathogenesis 
of GBM in dogs (Pike et al. 2004, Gookin et al. 2015, Kesimer 
et al. 2015). Previously proposed associations in GBM forma-
tion have included hyperlipidaemia (Kutsunai et al.  2014), 
hyperadrenocorticism, hypothyroidism (Mesich et al.  2009), 
increased serum leptin (Lee et al.  2017), neonicotinoids 
(Gookin et al. 2015) and a possible genetic mutation in Shet-
land sheepdogs that has been subsequently disputed (Mealey 
et al. 2010, Cullen et al. 2014). These factors may increase the 
risk of GBM, possibly by altering gall bladder motility (Tsu-
kagoshi et al.  2012) or altering the composition of bile and 
mucin within the gall bladder (Kook et al. 2012). Some pure-
breed dogs are at increased risk of GBM formation, including 
Shetland sheepdogs, miniature schnauzers, Pomeranians, Chi-
huahuas, American cocker spaniels, Affenpinschers and Border 
terriers (BTs) (Aguirre et al. 2007, Kutsunai et al. 2014, Aller-
ton et al. 2018).
Breed associated disease studies in BTs have supported gluten 
sensitivity as the cause for paroxysmal gluten-sensitive dyskinesia 
(PGSD), a movement disorder homologous to paroxysmal non 
kinesigenic dyskinesia observed in people (Jankovic & Demirki-
ran 2002, Black et al. 2014, Lowrie et al. 2015, 2016). Investigators 
established this link by documenting serum anti-gliadin IgG (AGA 
IgG) and anti-canine transglutaminase-2-IgA (TG2 IgA), (markers 
of gluten sensitivity in humans) were increased in BTs with PGSD 
and subsequently decreased after transition to a gluten free diet 
(Lowrie et al. 2015, 2018). These authors proposed that PGSD in 
dogs is part of a syndrome of gluten sensitivity in the BT breed, 
including gastrointestinal and dermatological signs, representing a 
systemic gluten associated disease (Lowrie et al. 2016, 2018).
In coeliac disease in humans, gall bladder sludge formation 
can be identified due to a reduction in gall bladder motility 
(Wang et al. 2017) and this hypomotility is attributed to a reduc-
tion in cholecystokinin (CCK) secretion (Maton et al.  1985, 
Upp et al. 1987, Fraquelli 1999, Wang et al. 2017). CCK is an 
endogenous peptide that stimulates pancreatic enzyme release 
and gall bladder contraction and delays gastric emptying (Hall 
et al.  2016). In humans suffering from coeliac disease it has 
been demonstrated that transition to a gluten free diet results 
in increased CCK concentration and subsequently increased gall 
bladder contractility (Maton et al. 1985).
Based on this link and the known history of gluten sensitivity in 
BTs, it was hypothesized that GBM formation in BTs is part of the 
proposed systemic gluten associated disease. Therefore, the primary 
aim of this study was to determine if serological indices of gluten 
sensitivity (increased AGA IgG and TG2 IgA) are significantly asso-
ciated with decreased CCK concentrations in BTs with GBM.
MATERIALS AND METHODS
Study population
For this pilot study, medical records were retrospectively reviewed 
to identify all dogs with a diagnosis of GBM presented to Lang-
ford Vets Small Animal Referral Hospital (LVS) between January 
1, 2011 and January 1, 2018. Ethical approval was granted by 
the Animal Welfare and Ethical Review Body (VIN/17/038) and 
Faculty Health Sciences Research Ethics Committee (FREC) at 
the University of Bristol.  Dogs were identified using the key-
words “mucocoele” and “mucocele.” From January 2, 2018 to 
January 7, 2019, prospective enrolment was undertaken for dogs 
similarly presenting with GBM to LVS and Willows Veterinary 
referrals, to appropriately increase the sample size calculated 
using the online programme http://biostat.mc.vanderbilt.edu/
wiki/Main/PowerSampleSize. This sample size calculation used 
a power of 0.8 and significance level of 0.05. A previous paper 
looking at CCK in humans with coeliac disease gave a reference 
standard deviation of 2.4 pg/mL (Fraquelli et al.  1999). This 
sample size calculation, based on an expected difference of 2.4 
in the mean concentration of CCK, determined the minimum 
number of dogs required in each group to detect that difference 
would be 15. A control group of BTs with non‐biliary tract dis-
orders presenting to LVS was also recruited for inclusion, ret-
rospectively within the same study period January 1, 2011 to 
January 1, 2018, and prospectively from January 2, 2018 to 
January 7, 2019.
A “Biobank” store at LVS was searched for residual fasted 
serum samples for analysis from both GBM and control dogs. 
For canine cases enrolled prospectively, residual fasted serum was 
collected and stored within that “Biobank” at −80°C until analy-
sis. All samples were derived from residual material after routine 
clinical investigations with owner permission obtained via a con-
sent form, signed on admission to the hospital.
Medical records were searched, and information collected, to 
include where available: breed, age, sex, neutered status, body-
weight, current and historical dietary history. For GBM cases, 
additional data recorded included histopathology results from 
the gall bladder and liver; culture results for bile, liver and gall 
bladder wall; the presence or absence of gall bladder rupture (as 
recorded in the ultrasound or surgical reports). We also looked 
to identify and describe the presence of underlying endocrinopa-
thies, results for endocrine testing for hypothyroidism, diabetes 
mellitus and hyperadrenocorticism were assessed. Results were 
collected from either historic or current medical records includ-
ing: blood glucose, thyroxine and thyroid stimulating hormone 
(T4/TSH), adrenocorticotrophic hormone (ACTH) stimulation 
test and low dose dexamethasone suppression test (LDDST).
For inclusion in the GBM group, dogs required: an abdominal 
ultrasound or CT scan reviewed by a board-certified radiologist 
or supervised resident in training with a diagnosis of GBM as 
per previously described criteria; immobile bile with a striated or 
stellate pattern (Choi et al. 2014). All dogs required an imaging 
confirmed diagnosis of GBM, and for dogs where histopathology 
was performed, evidence of mucinous hyperplasia was required 
to confirm the imaging diagnosis.
For inclusion in the control group, dogs required an abdomi-
nal ultrasound or CT, reviewed by a board-certified radiologist 
or resident in training, with no evidence of biliary disease; all of 
the animals in this control group were BTs. Criteria for no evi-
dence of biliary disease included: a normal biliary tree on ultra-
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sound showing a normal gall bladder wall thickness (<2 mm, 
(Nyland & Hager 1985)) and no evidence of gall bladder wall 
oedema (thickened gallbladder wall with a layered appearance 
and hypoechoic central layer) and on CT or ultrasound, no 
evidence of choleliths (hyperechoic structure causing acoustic 
shadowing), no evidence of biliary sludge (hyperechoic floccules 
within the gall bladder) and no evidence of a GBM (based on the 
prior inclusion criteria listed). These animals had this imaging 
performed within 48 hours of their blood sampling.
All animals also required a dietary history for review and no 
previous history compatible with PGSD (clinical signs of a move-
ment disorder suspected to be consistent with PGSD, with no 
evidence of pre or post-ictal signs and involuntary movement of 
one or more limbs whilst remaining conscious) recorded in their 
clinical and historical notes.
Serology
All samples were measured for concentrations of anti-gliadin IgG 
(AGA IgG), anti-canine transglutaminase-2-IgA autoantibodies 
(TG2 IgA) and CCK. These were determined by enzyme linked 
immunosorbent assay (ELISA) according to manufacturer’s 
guidelines (AGA IgG and TG2 IgA: ZEDIRA GmbH Darm-
stadt, Germany, CCK: Biomatik™, Ontario, Canada) and as 
previously detailed (AGA IgG and TG2 IgA: Lowrie et al. 2015, 
CCK: Noh et al. 2016). All serum samples were stored at −80°C 
until they were assayed in duplicate, alongside controls and stan-
dards, and their average value reported for analysis. All washing 
steps were performed by a BioTek 50 TS automated micro-
plate washer and optical density measurements determined by a 
Thermo Scientific Multiskan GO spectrophotometer.
Briefly, for anti-canine TG2 IgA detection, the microti-
ter plate was coated with canine TG2 antigens and the surface 
blocked with bovine serum albumin prior to use with canine sera 
and control samples. Bound antibodies against canine TG2 were 
detected by incubation with peroxidase-conjugated secondary 
antibody against canine IgA. The peroxidase converts a substrate 
(tetramethylbenzidine) into a blue product that with the addi-
tion of the stop product (0.2 M H2SO4) turns yellow. Negative 
control values were recorded using a buffer and conjugate.
For IgG anti-gliadin antibodies, a purified gliadin-coated 
microtiter plate was used. Detection of bound anti-gliadin anti-
bodies resulted from incubation with peroxidase-conjugated sec-
ondary antibody against canine IgG, conversion of substrate and 
addition of stop solution as described above for anti-canine TG2 
antibody. Negative control values were recorded using a buffer 
and conjugate.
CCK was measured via competitive inhibition ELISA using 
pre-coated microplates containing a monoclonal antibody spe-
cific for CCK. Samples, standards and blanks were incubated 
alongside biotin labelled CCK so that, with the addition of 
peroxidase-conjugated avidin, the subsequent conversion of 
substrate (tetramethylbenzidine) was inversely proportional to 
sample CCK concentration. Using a commercial software pro-
gramme (CurveExpert Basic 2.0) a standard curve was produced 
using regression analysis, from which serum CCK concentrations 
could be extrapolated, supplementary file Appendix 1.
Statistical analysis
Data were analysed using a commercial computer software pro-
gramme (Microsoft Excel™) and commercial statistical package 
(SPSS statistics, v.26 IBM corps). Results were identified to be 
non-normally distributed using Shapiro-Wilks test. The Indepen-
dent Samples Kruskall-Wallis test was used to assess if there was 
a statistical difference in the TG2 IgA, AGA IgG and CCK val-
ues as well as the ages, between BTs with GBM, non-BTs with 
GBM and the control group of BTs. Pairwise comparisons were 
then performed, with significant values adjusted by the Bonfer-
roni correction for multiple tests, with statistical significance set 
at P < 0.05.
RESULTS
Non-BTs with GBM
Seventeen non-BTs with GBM were identified and met the inclusion 
criteria. These dogs were a variety of breeds including: Jack Russell 
terrier (3), Shetland sheepdog (3), miniature schnauzer (2), bichon 
frise (2), Crossbreed (1), English bull terrier (1), Siberian husky (1), 
poodle (1), Pomeranian (1), shih-tzu (1) and Cavalier King Charles 
spaniel (1). There were 5 neutered females, 1 intact male and 11 
neutered males. The median age at diagnosis was 9.5 years (range 
2.3y −14.1y), median weight was 11.4 kg (range 2.7–30.1 kg). All 
dogs in this group were fed a commercial dog food.
BTs with GBM
Fifteen BTs with GBM were identified who met the inclusion 
criteria. There were two intact females, six neutered females, two 
intact males and five neutered males. The median age at diagno-
sis was 10.4 years (range 5.1y–13.3y), median weight was 9.0 kg 
(range 7.0–12.0 kg). All dogs were fed a commercial dog food.
Control BTs
Fourteen control BTs were diagnosed with other conditions, 
with no evidence of biliary disease on abdominal imaging. Other 
conditions included gastrointestinal disease [acute gastroenteritis 
(2), gastric foreign body (1), pancreatitis (1) and chronic enter-
opathy (1)], liver disease [acute hepatitis (2) and portosystemic 
shunt (1)], neurological disease (4), pyometra (1) and syncope 
(1). There was one intact female, four neutered females, one 
intact male and eight neutered males. The median age at diagno-
sis was 6.4 years (range 1.6–13years) median weight was 8.3 kg 
(range 6.5–10.1 kg). All dogs in this group were fed a commer-
cial dog food.
Between the three groups, there was a significant difference 
between the ages of the control and BT GBM group (P = 0.045) 
and control and non-BT GBM group (P = 0.021).
Gall bladder histopathology
In total, 18 of 32 dogs had gall bladder histopathology performed 
with all of these dogs having a histopathological diagnosis con-
sistent with a GBM, 7 of 17 non-BTs and 11 of 15 were BTs. 
In the remainder of dogs, histopathology was not performed and 
the diagnosis of GBM was made on imaging confirmation alone. 
L. Barker et al.
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Gall bladder rupture was identified on abdominal ultrasound or 
recorded in the surgical report in 4 of 16 BTs and 8 of 17 non-BTs.
Liver histopathology
Liver histopathology was performed in 5 of 17 non-BTs with 
GBM, and identified: portal fibrosis with bile duct proliferation 
and parenchymal necrosis (n = 1), biliary hyperplasia and por-
tal and pericellular fibrosis (1), extrahepatic cholestasis (1), mild 
lymphoplasmacytic cholangiohepatitis (1), and severe chronic 
hepatitis with fibrosis (1).
Liver histopathology was perfomed in 6 of 15 BTs with GBM 
group, and identified: neutrophilic cholangiohepatitis (1), mixed 
lymphoplasmacytic and neutrophilic cholangiohepatitis with 
cholestasis (2), chronic extrahepatic cholestasis and pericellular 
fibrosis (1), nodular hyperplasia with mixed neutrophilic, lym-
phoplasmacytic cholangiohepatitis and portal fibrosis (1) and 
multifocal hepatocyte necrosis with patchy, mild pericellular 
fibrosis and extrahepatic cholestasis (1).
Culture results
Gall bladder wall or bile culture was performed. In BTs with 
GBM, 11 of 15 had culture performed but a positive culture was 
only identified in one dog; a positive growth of Escherichia coli 
in both the bile and gall bladder wall in this dog. In non-BTs 
with GBM, 9 of 17 had culture performed and a positive culture 
was found in 4 of 9 of these dogs. Cultures were positive for 
Escherichia coli in two dogs, one from the gall bladder wall and 
one from the bile. One dog had a positive culture of Lactobacillus 
from the gall bladder wall and one dog had a positive culture of 
Serratia marcescens from the gall bladder wall.
Liver culture was performed. In BTs with GBM, 5 of 15 BTs 
had culture performed and no positive cultures were identified. 
In non-BTs with GBM, 5 of 17 had culture performed and one 
dog had a positive culture with a growth of Clostridia spp.
Serum testing
Values of TG2 IgA for control BTs ranged from 0.07 to 1.14 
(median 0.41), for BTs with GBM from 0.18 to 1.67 (median 
0.73) and for non-BTs with GBM from 0.1 to 1.64 (median 
0.60). There was a significant difference in TG2 IgA between 
the groups, and on pairwise comparison, the TG2 IgA was sig-
nificantly increased in BTs with GBM compared to control BTs, 
P = 0.015 (Fig. 1), the P value was still significant when adjusted 
for multiple comparison (P = 0.045).
Concentrations for CCK in control BTs ranged from 9 to 
397 pg/mL (median 103 pg/mL), in BTs with GBM from 6 to 
45 pg/mL (median 13 pg/mL) and for non-BTs with GBM from 
6 to 306 pg/mL (median 45 pg/mL). There was a significant 
difference in CCK between the groups, and on pairwise com-
parisons, the CCK was significantly lower in BTs with GBM 
compared to control BTs, P = 0.007 (Fig. 2), the P value was still 
significant when adjusted for multiple comparison (P = 0.016).
Values of AGA IgG for control BTs ranged from 0.08 to 
1.89 (median 0.45), for BTs with GBM from 0.11 to 3.16 
(median 0.36) and for non-BTs GBM from 0.08 to 0.27 
(median 0.15). No statistically significant difference was noted 
in AGA IgG between the groups, P = 0.58 (Fig. 3), multiple 
comparisons were not performed because the overall test did 
not show significance.
Pearson’s correlation coefficient found no significant correla-
tion between values of CCK and either TG2 IgA (−0.05) or AGA 
IgG (−0.13), Figs. 4a, b.
Endocrine disease
There were four dogs with diagnosed endocrinopathies. Two of 
which had multiple endocrinopathies; a non-BT GBM with con-
current hypothyroidism and hyperadrenocorticism, on treatment 
with thyroxine supplementation and not receiving treatment 
for hyperadrenocorticism at the time of referral, and a BT with 
GBM with concurrent hypothyroidism and diabetes mellitus, on 
treatment with thyroxine supplementation and insulin therapy. 
The remaining two dogs were one non-BT with GBM and one 
BT with GBM, and both presented with hyperadrenocorticism, 
and were diagnosed based on consistent clinical signs and one on 
ACTH stimulation test and the other on LDDST, neither dog 
was receiving treatment at the time of presentation (Table 1).
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FIG 1. Box plots demonstrating the transglutaminase-2 IgA (TG2 IgA) 
in each group of dogs. The solid line through represents the median. 
Control border terriers { (Control BT n = 14.) Border terrier gall 
bladder mucocoeles △ (BT GBM n = 15), Non-border terrier gall bladder 
mucocoeles ◇ (Non-BT GBM n = 17)
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FIG 2. Dot plots demonstrating the cholecystokinin (CCK) in each group 
of dogs. The solid line through represents the median. Control border 
terriers {(Control BT n = 14.) Border terrier gall bladder mucocoeles 
△ (BT GBM n = 15), Non-border terrier gall bladder mucocoeles ◇ 
(Non-BT GBM n = 17)
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DISCUSSION
This is the first study to evaluate BTs with GBM for markers 
of gluten intolerance, and may suggest a possible mechanism 
for GBM formation in the BT. Our study identified serological 
evidence of reduced CCK and increased TG2 IgA relatively in 
BTs with GBM compared to control BTs without any imaging 
evidence of biliary disease. These results are in part homologous 
to gall bladder disease identified in human coeliac disease, where 
decreased levels of CCK are seen, causing gall bladder hypomo-
tility (Maton et al. 1985, Upp et al. 1987, Fraquelli 1999), and 
this has been associated with biliary sludge formation (Wang 
et al. 2017) suggesting that there could be an association between 
GBM formation and a similar gluten associated immunological 
disease process in the BT.
Gluten sensitivity in humans is an immunological response 
to the ingestion of gluten that can cause varying systemic dis-
eases, including gastrointestinal and extra-gastrointestinal, 
which result in varied clinical signs including neurological and 
dermatological abnormalities. Diagnosis involves identifying 
serological evidence of antibodies to gliadin or auto-antibodies 
to transglutaminases (Lewis & Scott 2010). Gluten sensitivity 
in dogs is less well described, with gluten sensitive gastroin-
testinal disease identified in several breeds including the BT, 
soft-coated Wheaten terrier and Irish setter (Hall & Batt 1992, 
Vaden et al. 2000, Lowrie et al. 2016). Neurological and der-
matological manifestations of gluten sensitivity appear to have 
only been identified in the BT (Lowrie et al. 2015, 2016). Our 
study has identified an increase in TG2 IgA to support serologi-
cal evidence of autoantibodies to this transglutaminase in BTs 
with GBM and supporting the hypothesis that a similar immu-
nological disorder may exist within BTs with GBM. However, 
we did not identify a significant difference within the AGA IgG 
between these groups, compared to previous studies assessing 
gluten sensitivity within the BT breed (Lowrie et al. 2018). This 
previous study used healthy controls so this may have affected 
the results we achieved. Additionally our knowledge of gluten 
sensitivity within dogs and specifically the BT breed is still lim-
ited, and subsequently this pilot study may have identified that 
there is variation in the accuracy of this ELISA between differ-
ent gluten-related disease processes. Alternatively, this finding 
could represent a type II error, as our power calculation was 
based on a human study related to CCK, meaning this study 
could have been underpowered to identify a serological differ-
ence. Finally, the difference could relate to the sensitivity and 
specificity or predictive values of these antibody tests performed. 
In human coeliac disease, the single most sensitive and specific 
serological marker of coeliac disease is the IgA anti-transgluta-
minase 2 (IgA TG2), which was significantly increased in our 
GBM BT group. The anti-gliadin antibody (IgG AGA) has a 
lower sensitivity and specificity, leading to diminished utility of 
the marker for coeliac diagnosis in people, especially with the 
introduction of newer generations of anti-gliadin antibody tests 
that use disease specific deamidated gliadin peptides to optimise 
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FIG 3. Box plots demonstrating the anti-gliadin IgG (AGA IgG) in each 
group of dogs. The solid line through represents the median. Control 
border terriers {(Control BT n = 14.) Border terrier gall bladder 
mucocoeles △ (BT GBM n = 15), Non-border terrier gall bladder 
mucocoeles ◇ (Non-BT GBM n = 17)
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FIG 4. (a) Scatter plot demonstrating (the correlation of) 
transglutaminase-2 IgA (TG2 IgA) values with the CCK (cholecystokinin) 
concentration in Border terriers with gall bladder mucocoeles (BT GBM). 
(b) Scatter plot demonstrating (the correlation of) anti-gliadin IgG 
(AGAIgG) values with the CCK (cholecystokinin) concentration in Border 
terriers cholecystokinin) concentration in Border terriers
Table 1. Number of previously diagnosed endocrinopathies
Cases of endocrine 
disease
BTs GBM 
n = 17
Non-BTs GBM 
N = 15
Control BTs 
N = 9
Diabetes mellitus (% of 
all cases)
1 (5%) – –
Hyperadrenocorticism 
(% of all cases)
1 (5%) 2 (13%) –
Hypothyroidism (% of 
all cases)
1 (5%) 1 (6%) –
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test sensitivity and specificity (Briani et al.  2008). Therefore, 
this pilot study suggests that a gluten-related disorder could 
be involved in GBM formation in BTs, but further studies are 
warranted, including measurement of the deamidated gliadin in 
these patients too.
Gall bladder contraction is controlled by a number of neuropep-
tides including CCK (Krishnamurthy & Krishnamurthy  1997, 
Hall et al.  2016). Therefore, the identification of a significant 
reduction in CCK in BTs with GBM supports that gall bladder 
hypomotility could be involved in the pathophysiology of muco-
coele formation in this breed. These results support previous stud-
ies which have hypothesized that GBM formation in dogs is due to 
a reduction in gall bladder motility (Tsukagoshi et al. 2012). The 
results from our study, suggest that GBM formation in the BT 
may have a similar pathophysiology to biliary disease identified in 
human coeliac disease, whereby a reduction in CCK levels causes 
gall bladder hypomotility. However, as significance was noted 
only within IgA TG2 it is possible another mechanism, unrelated 
to a gluten disorder is responsible for the reduction in GB motility 
identified. Further studies to examine standardised meal-induced 
gall bladder emptying in dogs with GBM and low serum CCK 
measurement are warranted to investigate this.
Interestingly in gluten sensitive BTs with PGSD, transition 
to a gluten free diet has been shown to cause an improvement in 
both clinical signs and a reduction in their serological antibody 
markers (Lowrie et al.  2018). In humans with coeliac disease, 
transition to a gluten free diet results in an increase in CCK lev-
els and subsequently increased gall bladder contraction, causing a 
reduction in biliary sludge formation (Wang et al. 2017). There-
fore, we propose that a dietary change to gluten free feeding 
could also be beneficial in the management of GBM formation 
in BTs, possibly due to a similar effect on gall bladder motility. 
However to truly explore the significance of a gluten free diet in 
GBM formation, a prospective randomised study assessing sero-
logical levels of TG2 IgA, AGA IgG and CCK in BTs with non-
surgical GBM before and after transition to a gluten free diet, 
alongside direct assessment of gall bladder emptying, would need 
to be performed.
The significance of a reduction in CCK is important due to 
its role in gall bladder motility within the BT breed, although 
it is possibly relevant in other breeds presenting with GBM, 
despite non-BT not having a significant reduction in CCK in 
our study. Previous work has identified hyperadrenocorticism as 
an associative factor in GBM cases (Kim et al. 2017), and dogs 
with hyperadrenocorticism have been shown to have a significant 
reduction in both CCK and leptin levels (Cho et al. 2014, Noh 
et al. 2016). Therefore, the finding of decreased CCK in dogs 
within this study and the previous identification of reduced CCK 
(and leptin) in dogs with hyperadrenocorticism suggest the cause 
of GBM in dogs with hyperadrenocorticism could also relate to 
gall bladder hypomotility. However, the roles of leptin and CCK 
in dogs with both GBM and concurrent endocrinopathies may 
be relevant and something to be explored in future studies.
Our study has a number of limitations. First, the samples for 
this study were collected retrospectively and stored within a “Bio-
bank,” so sample quality and storage time varied between samples. 
The full effect of storage on conducting the ELISAs is unknown. 
However, as all samples were stored in the same manner, it was 
thought likely that storage would have similarly affected all the 
samples within the three comparative groups. Specific canine 
data on in vitro stability for these antibodies and CCK are 
unknown, but likely comparable to other proteins and human 
studies. They are therefore expected to be similar with accept-
able sample storage in this study. The sample qualities (degree 
of haemolysis, icterus and lipaemia) were also similar between 
the groups. Another limitation of the study was within the con-
trol group, it was not possible to age match this group so there 
was a significant difference in the ages of the controls and GBM 
dogs, meaning this may have affected the significance of results 
achieved. Although not presenting with signs of PGSD, there is 
a possibility these control dogs would develop signs of PGSD 
or other gluten related diseases in the future, which could have 
adversely affected the results and their significance, however, the 
age for seroconversion is not known. Previously there has been 
some overlap in the measurements of assays for gluten intoler-
ance between BTs with PGSD and gastrointestinal and dermato-
logical signs (Lowrie et al. 2018), it is possible there some overlap 
has also occurred within the dogs in this study. Additionally it is 
known in humans that CCK will increase with age (MacIntosh 
et al. 1999), therefore, the finding of a higher CCK within our 
control group despite them being younger further supports this 
was a true finding and the significant age difference is unlikely 
to have affected this result. Also within the control group, some 
of the animals presented with gastrointestinal signs which may 
have affected the ELISA results, especially the CCK. However, 
the decision to leave these animals within the control group was 
made as the study aim was to assess a difference between dogs 
with GBM and those without, many of which would have com-
plex GI diseases, so the control group including similar diseases 
was deemed an appropriate selection. Additionally we ran CCK 
on these samples, without a known history of fat content of the 
food or exact timing of feeding, however all ELISAs were run 
on samples which were starved for a minimum of 8 hours. A 
previous study showed dogs with GBM had significantly higher 
pre-prandial CCK than control dogs (Noh et al. 2016), and in 
humans lower basal CCK has been noted in patients with coeliac 
disease compared to controls (Thompson et al. 1982). Therefore 
it seemed appropriate to use pre-prandial, basal samples in these 
dogs, and these results were deemed to be accurate for CCK mea-
surement. Finally, a significant difference was noted for CCK 
and TG2 IgA between the BTs with GBM and control BTs but 
no difference between the two GBM groups. These results sug-
gest that these findings may not be specific to GBM within the 
BT breed, and could be contributing to GBM disease in other 
breeds. The assays performed for TG2 IgA and AGA IgG have 
only been described in BTs previously, so their differing interpre-
tation in other breeds could have affected these results. Addition-
ally it could be considered that a mechanism unrelated to gluten 
sensitivity, and solely affecting CCK and subsequently GBM 
motility may be an important factor for GBM formation. To 
investigate these possibilities further, larger and additional stud-
ies would be needed.
Gluten sensitivity in BTs with GBM
Journal of Small Animal Practice  •  © 2020 The Authors. Journal of Small Animal Practice published by John Wiley & Sons Ltd on behalf of 7 
British Small Animal Veterinary Association 
In conclusion, this study provides insights on the potential 
pathophysiology of GBM within the BT breed. This study 
has identified serological evidence of auto-antibody formation 
against TG2, alongside a reduction in CCK, as possible mark-
ers of risk for GBM disease in BT. The results from this study 
suggest a gluten-related disorder and reduction in gall bladder 
motility may then be associated with GBM formation in BTs. 
However, further prospective studies are needed to elucidate 
whether altered gall bladder motility has an effect on GBM for-
mation, and whether feeding of a gluten free diet may then be 
beneficial in the successful management of non-surgical GBM 
disease in BTs.
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